Fontan circulation: Success or failure?

Canadian Journal of Cardiology

Volumn 29, Issue 7, 2013, Pages 811-820

  Mondésert, Blandine ^a   Marcotte, François ^a   Mongeon, François Pierre ^a   Dore, Annie ^a   Mercier, Lise Andrée ^a   Ibrahim, Reda ^a   Asgar, Anita ^a   Miro, Joaquim ^a   Poirier, Nancy ^a   Khairy, Paul ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASCITES; BLOOD CLOTTING DISORDER; BRONCHITIS; CLINICAL FEATURE; CLINICAL RESEARCH; COUGHING; CYANOSIS; DYSPNEA; ELASTOGRAPHY; FONTAN PROCEDURE; HEART HEMODYNAMICS; HEART VENTRICLE FUNCTION; HUMAN; INCIDENCE; KNOWLEDGE; LIVER DYSFUNCTION; MORTALITY; MULTICENTER STUDY (TOPIC); OPERATION DURATION; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PREVALENCE; PROTEIN LOSING GASTROENTEROPATHY; PULMONARY ARTERY; REENTRY TACHYCARDIA; REVIEW; SINUS NODE DISEASE; THROMBOCYTOPENIA; TREATMENT FAILURE; WEIGHT GAIN;

ADULT; CHILD; FONTAN PROCEDURE; HEART DEFECTS, CONGENITAL; HUMANS; POSTOPERATIVE COMPLICATIONS; TREATMENT FAILURE; VENTRICULAR DYSFUNCTION;

EID: 84879500466     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.12.009     Document Type: Review

References (91)

1. Khairy P., Poirier N., Mercier L.A. Univentricular heart. Circulation 2007, 115:800-812.
2. de Leval M.R. The Fontan circulation: a challenge to William Harvey?. Nat Clin Pract Cardiovasc Med 2005, 2:202-208.
3. Warnes C.A., Williams R.G., Bashore T.M., et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. JAm Coll Cardiol 2008, 52:e143-e263.
4. Silversides C.K., Salehian O., Oechslin E., et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions. Can J Cardiol 2010, 26:e98-117.
5. Fontan F., Baudet E. Surgical repair of tricuspid atresia. Thorax 1971, 26:240-248.
6. de Leval M.R., Kilner P., Gewillig M., Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations. Experimental studies and early clinical experience. JThorac Cardiovasc Surg 1988, 96:682-695.
7. d'Udekem Y., Iyengar A.J., Cochrane A.D., et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation 2007, 116:I157-I164.
8. Rogers L.S., Glatz A.C., Ravishankar C., et al. 18 years of the Fontan operation at a single institution: results from 771 consecutive patients. JAm Coll Cardiol 2012, 60:1018-1025.
9. Khairy P., Fernandes S.M., Mayer J.E., et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 2008, 117:85-92.
10. Diller G.P., Giardini A., Dimopoulos K., et al. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J 2010, 31:3073-3083.
11. Valente A.M., Bhatt A.B., Cook S., et al. The CALF (Congenital Heart Disease in Adults Lower Extremity Systemic Venous Health in Fontan Patients) study. JAm Coll Cardiol 2010, 56:144-150.
12. Goldberg D.J., Shaddy R.E., Ravishankar C., Rychik J. The failing Fontan: etiology, diagnosis and management. Exp Rev Cardiovasc Ther 2011, 9:785-793.
13. Anderson P.A., Sleeper L.A., Mahony L., et al. Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. JAm Coll Cardiol 2008, 52:85-98.
14. Piran S., Veldtman G., Siu S., Webb G.D., Liu P.P. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation 2002, 105:1189-1194.
15. Eicken A., Fratz S., Gutfried C., et al. Hearts late after Fontan operation have normal mass, normal volume, and reduced systolic function: a magnetic resonance imaging study. JAm Coll Cardiol 2003, 42:1061-1065.
16. Kouatli A.A., Garcia J.A., Zellers T.M., Weinstein E.M., Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 1997, 96:1507-1512.
17. Shaddy R.E., Boucek M.M., Hsu D.T., et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007, 298:1171-1179.
18. Guazzi M., Vicenzi M., Arena R., Guazzi M.D. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011, 4:8-17.
19. Goldberg D.J., French B., Szwast A.L., et al. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Ped Cardiol 2012, 33:689-696.
20. Cohen M.S., Zak V., Atz A.M., et al. Anthropometric measures after Fontan procedure: implications for suboptimal functional outcome. Am Heart J 2010, 160:1092-1098.
21. Kendall T.J., Stedman B., Hacking N., et al. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. JClin Pathol 2008, 61:504-508.
22. Ghaferi A.A., Hutchins G.M. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. JThorac Cardiovasc Surg 2005, 129:1348-1352.
23. Kiesewetter C.H., Sheron N., Vettukattill J.J., et al. Hepatic changes in the failing Fontan circulation. Heart 2007, 93:579-584.
24. Camposilvan S., Milanesi O., Stellin G., Pettenazzo A., Zancan L., D'Antiga L. Liver and cardiac function in the long term after Fontan operation. Ann Thorac Surg 2008, 86:177-182.
25. Babaoglu K., Binnetoglu F.K., Aydogan A., et al. Hepatic adenomatosis in a 7-year-old child treated earlier with a Fontan procedure. Ped Cardiol 2010, 31:861-864.
26. Saliba T., Dorkhom S., O'Reilly E.M., Ludwig E., Gansukh B., Abou-Alfa G.K. Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastro Hepatol 2010, 22:889-891.
27. Baek J.S., Bae E.J., Ko J.S., et al. Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors. Heart 2010, 96:1750-1755.
28. Zhou K., Gao C.F., Zhao Y.P., et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. JGastroenterol Hepatol 2010, 25:1569-1577.
29. Imbert-Bismut F., Ratziu V., Pieroni L., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
30. Cales P., Oberti F., Michalak S., et al. Anovel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373-1381.
31. Lebray P., Varnous S., Charlotte F., Varaut A., Poynard T., Ratziu V. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 2008, 48:2089.
32. Sandrin L., Fourquet B., Hasquenoph J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-1713.
33. Millonig G., Friedrich S., Adolf S., et al. Liver stiffness is directly influenced by central venous pressure. JHepatol 2010, 52:206-210.
34. Jarcuska P., Janicko M., Veseliny E., Jarcuska P., Skladany L. Circulating markers of liver fibrosis progression. Int J Clin Chem 2010, 411:1009-1017.
35. Goyal N., Jain N., Rachapalli V., Cochlin D.L., Robinson M. Non-invasive evaluation of liver cirrhosis using ultrasound. Clin Radiol 2009, 64:1056-1066.
36. Huwart L., Sempoux C., Vicaut E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008, 135:32-40.
37. Bridges N.D., Lock J.E., Mayer J.E., Burnett J., Castaneda A.R. Cardiac catheterization and test occlusion of the interatrial communication after the fenestrated Fontan operation. JAm Coll Cardiol 1995, 25:1712-1717.
38. Reinhardt Z., Uzun O., Bhole V., et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010, 20:522-525.
39. Giardini A., Balducci A., Specchia S., Gargiulo G., Bonvicini M., Picchio F.M. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008, 29:1681-1687.
40. Horai T., Bhama J.K., Fontes P.A., Toyoda Y. Combined heart and liver transplantation in a patient with situs ambiguous. Ann Thorac Surg 2011, 91:600-601.
41. Cannon R.M., Hughes M.G., Jones C.M., Eng M., Marvin M.R. Areview of the United States experience with combined heart-liver transplantation. Transpl Int 2012, 25:1223-1228.
42. Deal B.J., Jacobs M.L. Management of the failing Fontan circulation. Heart 2012, 98:1098-1104.
43. Jahangiri M., Kreutzer J., Zurakowski D., Bacha E., Jonas R.A. Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation. JThorac Cardiovasc Surg 2000, 120:778-782.
44. Odegard K.C., McGowan F.X., Zurakowski D., et al. Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. JThorac Cardiovasc Surg 2003, 125:1260-1267.
45. Kim S.J., Kim W.H., Lim H.G., Lee J.Y. Outcome of 200 patients after an extracardiac Fontan procedure. JThorac Cardiovasc Surg 2008, 136:108-116.
46. Marrone C., Galasso G., Piccolo R., et al. Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis. Pediatr Cardiol 2011, 32:32-39.
47. Robbers-Visser D., Miedema M., Nijveld A., et al. Results of staged total cavopulmonary connection for functionally univentricular hearts; comparison of intra-atrial lateral tunnel and extracardiac conduit. Eur J Cardiothorac Surg 2010, 37:934-941.
48. Monagle P., Cochrane A., Roberts R., et al. Amulticenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. JAm Coll Cardiol 2011, 58:645-651.
49. Canter C.E. Preventing thrombosis after the Fontan procedure not there yet. JAm Coll Cardiol 2011, 58:652-653.
50. Rychik J. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis 2007, 2:288-300.
51. Mertens L., Hagler D.J., Sauer U., Somerville J., Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. JThorac Cardiovasc Surg 1998, 115:1063-1073.
52. Gewillig M., Brown S.C., Eyskens B., et al. The Fontan circulation: who controls cardiac output?. Interact Cardiovasc Thorac Surg 2010, 10:428-433.
53. Uzun O., Wong J.K., Bhole V., Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 2006, 82:e39-e40.
54. Ostrow A.M., Freeze H., Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 2006, 82:695-700.
55. Rychik J., Gui-Yang S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol 2002, 90:672-674.
56. Lenz D., Hambsch J., Schneider P., et al. Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection?. Critical Care 2003, 7:185-190.
57. Cohen M.I., Rhodes L.A., Wernovsky G., Gaynor J.W., Spray T.L., Rychik J. Atrial pacing: an alternative treatment for protein-losing enteropathy after the Fontan operation. JThorac Cardiovasc Surg 2001, 121:582-583.
58. Mertens L., Dumoulin M., Gewillig M. Effect of percutaneous fenestration of the atrial septum on protein-losing enteropathy after the Fontan operation. Br Heart J 1994, 72:591-592.
59. Rychik J., Rome J.J., Jacobs M.L. Late surgical fenestration for complications after the Fontan operation. Circulation 1997, 96:33-36.
60. Donnelly J.P., Rosenthal A., Castle V.P., Holmes R.D. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. JPediatr 1997, 130:474-478.
61. Rychik J., Piccoli D.A., Barber G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol 1991, 68:819-821.
62. Thacker D., Patel A., Dodds K., Goldberg D.J., Semeao E., Rychik J. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2010, 89:837-842.
63. Costello J.M., Steinhorn D., McColley S., Gerber M.E., Kumar S.P. Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. Pediatrics 2002, 109:e67.
64. DiCindio S., Theroux M., Costarino A.T., Cook S., O'Reilly R. Plastic bronchitis: a case report. Paed Anaesthesia 2004, 14:520-523.
65. Goldberg D.J., Dodds K., Rychik J. Rare problems associated with the Fontan circulation. Cardiol Young 2010, 20(suppl 3):113-119.
66. Ishman S., Book D.T., Conley S.F., Kerschner J.E. Plastic bronchitis: an unusual bronchoscopic challenge associated with congenital heart disease repair. Int J Pediatr Otorhinolaryngol 2003, 67:543-548.
67. Zaccagni H.J., Kirchner L., Brownlee J., Bloom K. Acase of plastic bronchitis presenting 9 years after Fontan. Pediatr Cardiol 2008, 29:157-159.
68. Do T.B., Chu J.M., Berdjis F., Anas N.G. Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature. Pediatr Cardiol 2009, 30:352-355.
69. Apostolopoulou S.C., Papagiannis J., Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. JHeart Lung Transplant 2005, 24:1174-1176.
70. Onoue Y., Adachi Y., Ichida F., Miyawaki T. Effective use of corticosteroid in a child with life-threatening plastic bronchitis after Fontan operation. JJapan Pediatr Soc 2003, 45:107-109.
71. Wilson J., Russell J., Williams W., Benson L. Fenestration of the Fontan circuit as treatment for plastic bronchitis. Pediatr Cardiol 2005, 26:717-719.
72. Wakeham M.K., Van Bergen A.H., Torero L.E., Akhter J. Long-term treatment of plastic bronchitis with aerosolized tissue plasminogen activator in a Fontan patient. Pediatr Critic Care Med 2005, 6:76-78.
73. Giannakoulas G., Dimopoulos K., Yuksel S., et al. Atrial tachyarrhythmias late after Fontan operation are related to increase in mortality and hospitalization. Int J Cardiol 2012, 157:221-226.
74. Stamm C., Friehs I., Mayer J.E., et al. Long-term results of the lateral tunnel Fontan operation. JThorac Cardiovasc Surg 2001, 121:28-41.
75. Lee J.R., Kwak J., Kim K.C., et al. Comparison of lateral tunnel and extracardiac conduit Fontan procedure. Interact Cardiovasc Thorac Surg 2007, 6:328-330.
76. Nurnberg J.H., Ovroutski S., Alexi-Meskishvili V., Ewert P., Hetzer R., Lange P.E. New onset arrhythmias after the extracardiac conduit Fontan operation compared with the intraatrial lateral tunnel procedure: early and midterm results. Ann Thorac Surg 2004, 78:1979-1988.
77. Khairy P., Poirier N. The extracardiac conduit is not the preferred Fontan approach for patients with univentricular hearts. Circulation 2012, 126:2516-2525.
78. Khairy P. EP challenges in adult congenital heart disease. Heart Rhythm 2008, 5:1464-1472.
79. Yap S.C., Harris L., Silversides C.K., Downar E., Chauhan V.S. Outcome of intra-atrial re-entrant tachycardia catheter ablation in adults with congenital heart disease: negative impact of age and complex atrial surgery. JAm Coll Cardiol 2010, 56:1589-1596.
80. Akca F., Bauernfeind T., Witsenburg M., et al. Acute and long-term outcomes of catheter ablation using remote magnetic navigation in patients with congenital heart disease. Am J Cardiol 2012, 110:409-414.
81. Triedman J.K., Alexander M.E., Love B.A., et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease. JAm Coll Cardiol 2002, 39:1827-1835.
82. Nakamura Y., Yagihara T., Kagisaki K., Hagino I., Kobayashi J. Ventricular performance in long-term survivors after Fontan operation. Ann Thorac Surg 2011, 91:172-180.
83. Fernandes S.M., McElhinney D.B., Khairy P., Graham D.A., Landzberg M.J., Rhodes J. Serial cardiopulmonary exercise testing in patients with previous Fontan surgery. Pediatr Cardiol 2010, 31:175-180.
84. Paridon S.M., Mitchell P.D., Colan S.D., et al. Across-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. JAm Coll Cardiol 2008, 52:99-107.
85. Giardini A., Hager A., Pace Napoleone C., Picchio F.M. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann Thorac Surg 2008, 85:818-821.
86. Le Gloan L., Mercier L.A., Dore A., et al. Pregnancy in women with Fontan physiology. Expert Rev Cardiovasc Ther 2011, 9:1547-1556.
87. Mitchell M.B., Campbell D.N., Ivy D., et al. Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. JThorac Cardiovasc Surg 2004, 128:693-702.
88. Goldberg D.J., French B., McBride M.G., et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation 2011, 123:1185-1193.
89. Rodefeld M.D., Coats B., Fisher T., et al. Cavopulmonary assist for the univentricular Fontan circulation: von Karman viscous impeller pump. JThorac Cardiovasc Surg 2010, 140:529-536.
90. Bhavsar S.S., Kapadia J.Y., Chopski S.G., Throckmorton A.L. Intravascular mechanical cavopulmonary assistance for patients with failing Fontan physiology. Artif Organs 2009, 33:977-987.
91. Haggerty C.M., Fynn-Thompson F., McElhinney D.B., et al. Experimental and numeric investigation of Impella pumps as cavopulmonary assistance for a failing Fontan. JThorac Cardiovasc Surg 2012, 144:563-569.